Member Info for RPStock

just listen at 56th minute

on conf. call on 23rd March, the external expert was asked question somewhere towards end and he said for such late line patients instead of response rate, disease control or survival can be the biomarker.

Hi Sang, primary endpoint can be found on clinical trial page which I believe is clinical benefit that includes SD. Company's rns dated 23rd March, 22 has heading "MRx0518 + Keytruda - Primary endpoint met in RCC". Are you saying company is lying on rns?

This is presentation of Asthma data we released (already rns released in Dec & Jan) so there doesn't need to be rns except if 4D feels may release rns about participation.

I wish they put video link instead of audio at first. Audio sounded bit irritating with lots of pauses and err, you know but when you see video it is much more informally set, Duncan looks relaxed (in audio you may feel he is using hey, look, fantastic Cathedral, steak, chicken etc. over phone as not able to get answer fluently but actually it is friendly video chat of course arranged by 6Degree PR)

https://www.youtube.com/watch?v=Pv_EC0_XJ_A

Apparently the last interview Duncan gave was video recorded: https://www.linkedin.com/posts/matthewpillar_businessofbiotech-biologic-gutbrainaxis-activity-6929409059183874048-hkkU?utm_source=linkedin_share&utm_medium=member_desktop_web
If anybody interested to see short clip with Duncan appearing clean shaved this time.
Matthew Pillar seems quite satisfied thanking 6Degree PR for introducing and claiming he learned a lot from Duncan

Sang, Cazoo valuation is almost $1 billion, don't see its cash equivalent to that (simplywall and last financial result). If you see vroom it was even 30-40 times on listing and much higher in 2020 and probably more assets. Buying/selling used cars and such high valuations is amazing, just wondering is there any MOAT as any competitor can come with online buy/sell of used cars. I am no expert and you must have done more research but for me 4D has better MOAT (patents, pipeline etc.). Unless 4D BoD is fraud (if it is then real daring to collaborate with Merck, Pfizer and US hospitals and listing on nasdaq as it could continue on AIM and raise locally instead of exposing to SEC filing etc.) and claiming good data and hiding bad data, 4D shouldn't have much trouble in raising funds. I feel its BoD don't intend to raise at low price else could have done bit more promotion before and after oncology update in March and raise some funds. Probably they did release Oncology update to attempt raise but if that was the case then real pathetic attempt as should have done much more efforts in wooing institutional and retail investors in Feb & March. In Chardan conf. CFO said they will be nimble and spend cash in most promising assets. 4D will certainly need to raise funds by next quarter but BoD's actions are weird. They either 1) Waiting for market conditions to improve or 2) trying to get funds from other sources. Hopefully we get clarity soon

Late trades before 4.30 looked like shorts reducing, few chunky blue ATs, last time like this was before RCC rns. Though yesterday with markets including nasdaq in deep red 4D couldn't go much high though good it finished flat. Let's see what next weeks bring.

$lbps very low volume these days and that allows some one to sell couple of hundred stocks in last 8 seconds every day to close couple of cents down than it is just before 4.29.52 pm US time. So manipulation just with 2-500 stocks

Where can I get information about their team? on LinkedIn page of 'Imaging Biometrics, LLC' 6 employees are seen but not much info and none of these are PhD.

2 patients in part A did get PR and at least one of them is still continuing in study. So if we add part A and part B, they have 2 PR and 6 SD out of 24 patients so 33% clinical benefit (PR or SD for more than 6 months).

Kaleido had failures in its programmes and not even 1 drug could reach phase 2 on the top its directors were holding very little (less than 0.5%)

Hi Sang, away most day so haven't gone through all messages but you are right about that covenant of keeping £7.5 million of cash on hand. Though I don't see Duncan/Alex nervous lately, in fact they are looking or showing confidence lately (were bit nervous looking last year). They are not showing panic and not promoting stock like they would do in case they need to raise soon. Also don't forget note in results about directors exploring source of finance that are available and reasonably confident (or something in that line) of getting that would provide cash for at least 12 months from date of preparation of accounts. So since these are 12 months from now, it won't be equity raise as they would raise at least $45 million (unless they are thinking of raising 10-20 million $ for time being). So probably director might be either exploring funds from some collaboration or Oxford or other lender.

Definitely if you believe in company and cash available this is the price to invest. I believe lots of 4D shareholders including me have increased their holdings averaging down since long but they won't have unlimited cash. If II not investing management needs to spend bit more efforts in promoting in retail investors. For example, even though I am not invested in Avacta, the way it presented rns for its result and held detailed management call through investor meeting company next day, it sells dreams to retail investors and probably increasing its base. They used words like excited and confident and high hope of collaborations mid year etc. in annual results even though they had just 1 product to give such hope. Maybe 4D management has good plan in place and don't want to promote much until Oliveira is done.

Didn't Morgan Stanley buy AGL shares in open market?

Thanks MHB, I was also wondering with same reading result rns. This gives some clarity and I agree with your comment. Thanks for sharing.

Duncan said in interview with IG lots of interesting news going to come out on MRX0518 oncology (Bavencio trial start, Lung cancer group data in combination with Keytruda, Pancreatic cancer trial data). I am excited for Lung Cancer study in combination with Keytruda, it it has similar result like RCC reported, that should have very positive effect (That will satisfy all conditions for Oxford Finance next tranche, Oliveira would have sold his current stake by then, prove in another type of Cancer). Feb 21 they had 24 patients enrolled 12 RCC, 9 NSCLC (Lung Cancer) and 3 bladder cancer patients. In latest RNS they have 47 enrolments, so 23 additional patients. Out of these 8 are in RCC group, so should have few more in NSCLC group as well. In addition 4D will start trial with Bavencio in bladder cancer in earlier stage patients and they already saw tumor reductions in bladder cancer group (read 3rd Feb 21 rns). So many things in pipeline

That site data is not trustworthy. It is showing him holding FBRX (which mostly he sold as I have seen somewhere 0% in that) and on 4D it was showing 0% few weeks back. But anyway Oliveira shound not be holding more than 1% now as the volume after last rns of him holding 2% has been quite high.

They seem very confident, interesting 3 paragraphs starting with "He also outlined" ending "resistance to checkpoint inhibitors"